Bharat Biotech starts Covaxin's at-risk manufacturing; expanding capacity

As India’s first indigenous Covid-19 vaccine candidate gets the nod for phase 3 trials, Hyderabad-based vaccine maker Bharat Biotech has not only started the at-risk manufacturing of its candidate Covaxin, but is also looking to ramp up capacities.

The first vaccine candidate will be an intra-muscular one, followed by intra-dermal and nasal ones, depending on test results. 

Besides setting up a second plant at its Genome Valley facility in Hyderabad to make Covaxin, the firm is looking for another site in the country to make the vaccine.

Speaking to Business Standard, Sai Prasad, executive director at Bharat Biotech International (BBIL), said: “We are